What if the best prostate cancer treatment doesn’t cut, burn, or destroy your vitality — yet still teaches your immune system to find and fight cancer throughout the body?
In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, explains how precision oncology and interventional radiology are redefining prostate cancer care. Instead of relying on radical surgery or radiation, Envita uses deep DNA/RNA sequencing, immune profiling, and 3D cone-beam imaging to guide minimally invasive, immune-centered procedures.
Dr. Prato discusses the risks of standard prostate surgery — including incontinence, erectile dysfunction, and long-term recurrence — and how precision targeting eliminates guesswork by treating the tumor directly and stimulating the immune system for long-term remission.
🎯 What You’ll Learn in This Episode:

• Why up to 50% of men experience PSA recurrence after prostate surgery

• How interventional oncology delivers treatment directly to the tumor site

• Why immune-based, precision care improves long-term outcomes

• The difference between radical surgery and image-guided microcatheter treatment

• How DNA, RNA, and spatial biology testing reveal cancer’s weak points

• Why deep mapping prevents recurrence and protects quality of life
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576
“The future of prostate cancer care is precise, personalized, and immune-centered.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493